ReviewInternational journal of chronic obstructive pulmonary disease2011
Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.
Review in International journal of chronic obstructive pulmonary disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2018Pooled it
- Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2015Pooled it
- Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2012Pooled it
- [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].Atencion primaria · 2012Guideline
- Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2012Pooled it
- Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.BMC pulmonary medicine · 2014Trial
- Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2013Trial
- A portable colorimetric chemosensing regime for ractopamine in chicken samples using μPCD decorated by silver nanoprisms.RSC advances · 2022Article
- COPD: maximization of bronchodilation.Multidisciplinary respiratory medicine · 2014Review
- A role of indacaterol in chronic obstructive pulmonary disease management: a turning point or crossroads?Journal of thoracic disease · 2013Article
- Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355.Clinical pharmacokinetics · 2013Article
- [Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis].Archivos de bronconeumologia · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchodilators are the cornerstone of severe chronic obstructive pulmonary disease (COPD) treatment to improve airflow, symptoms, exercise tolerance, and exacerbations. There is convincing evidence that regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators. Long-acting β-2-agonists include the twice-daily drugs formoterol and salmeterol and, more recently, once-daily indacaterol. Studies with head-to-head comparisons of long-acting bronchodilators are scant, but novel data from controlled trials with the once-daily β(2)-agonist indacaterol indicate superior bronchodilation and clinical efficacy of indacaterol at recommended doses over twice-daily long-acting β(2)-agonists, and at least equipotent bronchodilation compared with once-daily tiotropium. The recent therapeutic developments in COPD underscore a shift from short-acting bronchodilators with multiple dosings per day to reduced dosing frequency and prolonged duration of action, including once-daily treatment, with more consistent effects on various clinical outcomes. This review summarizes relevant clinical data for twice-daily β-2-agonists in COPD, and further focuses on novel data for once-daily indacaterol, including head-to-head comparison trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.